期刊文献+

小分子化合物丙戊酸促进大鼠坐骨神经的再生

Promotional effect of micromolecular compound valproic acid on the regeneration of sciatic nerve in rats
暂未订购
导出
摘要 目的:观察小分子化合物丙戊酸对周围神经再生的作用。方法:实验于2005-07/10在吉林大学中日联谊医院动物实验室完成。选用成年雄性Wistar大鼠15只,随机分为假手术组、模型组和丙戊酸组3组(n=5)。模型组和丙戊酸组大鼠切断右侧坐骨神经制备单纯坐骨神经轴突切断模型,然后即刻行神经吻合术,假手术组不切断坐骨神经。丙戊酸组大鼠在神经修复术后喂食含丙戊酸水(300mg/(kg·d))16周,使血浆浓度达到50mg/L。16周后,各组大鼠取坐骨神经及双侧胫骨前肌进行组织形态学检查,观察再生的有髓神经纤维和神经再支配的肌纤维数量及大小。结果:15只大鼠全部进入结果分析。①模型组和丙戊酸组再生的单个有髓神经纤维的大小明显小于假手术组(P<0.001);模型组和丙戊酸组中再生神经有髓纤维数量是假手术组的3倍(P<0.001);丙戊酸组大鼠中有髓神经纤维数量明显高于模型组(P<0.05)。②模型组和丙戊酸组大鼠神经再支配胫骨前肌中单个肌纤维大小明显小于假手术组(P<0.05),丙戊酸组再支配胫骨前肌肌纤维数量明显高于模型组(P<0.05)。结论:丙戊酸并不能影响神经再支配肌肉组织中肌纤维的大小,但可使神经再支配肌肉中肌纤维数量显著增加,进而增强大鼠坐骨神经再生能力,提示丙戊酸对人体周围神经损伤具有潜在的临床应用价值。 AIM: To study the role of micromolecular compound valproic acid (VPA) in the regeneration of peripheral nerves. METHODS: The experiment was conducted in the Animal Laboratory of China-Japan Union Hospital, Jilin University from July to October 2005. A total of 15 adult male Wistar rats were randomly divided into sham-operation group, model group and VPA group with 5 rats in each group. Rats in the model group and VPA group were cut off the sciatic nerve of the right side to establish simple sciatic nerve axotomy model, and then immediately conduct neuroanastomosis, while sciatic nerve of rats in the sham-operation group were not cut off. Rats in the vPA group were fed with water, in which VPA dissolved [(300 mg/(kg.d)] following neural prosthesis for 16 weeks to enable the plasma concentration reach to 50 mg/L. After 16 weeks, all rats were sacrificed for histomorphometric examination of sciatic nerves and bilateral anterior tibial muscles, and the number and size of myelinated nerve fibres and reinnervated muscle fibres were observed. RESULTS: A total of 15 rats all entered the final analysis.(1)The size of single myelinated nerve fibre that regenerated in the model group and VPA group was remarkably smaller than that of sham-operation group (P 〈 0.001); And the number of regenerated myelinated nerve fibres in the model group and VPA group was 3 times as that of the sham-operation group (P 〈 0.001), and that of the VPA group was markedly higher than that of model group (P 〈 0.05). (2)The size of single muscle fibre in reinnervated anterior tibial muscles of rats in the model group and VPA group was obviously smaller than that of the sham-operation group (P 〈 0.05), and the number of reinnervated anterior tibial muscles was significantly higher than that of the model group (P 〈 0.05). CONCLUSION: VPA is unable to influence the size of muscle fibres in reinnervated muscles, whereas it can increase the number of muscle fibres, and thus reinforcing the regeneration capacity of sciatic nerve in rats, which indicates that there is a potential clinical value of VPA in applying in human peripheral nerve injury.
出处 《中国临床康复》 CAS CSCD 北大核心 2006年第14期117-119,共3页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献16

  • 1Semkova I, Krieglstein J. Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res Brain Res Rev 1999;30(2):176-88
  • 2Weibel D,Kreutzberg GW,Schwab ME. Brain-derived neurotrophic factor (BDNF) prevents lesion-induced axonal die-back in young rat optic nerve.Brain Res 1995;679(2):249-54
  • 3Cui Q, Harvey AR.At least two mechanisms are involved in the death of retinal ganglion cells following target ablation in neonatal rats. J Neurosci 1995;15( 12):8143-55
  • 4Pardridge WM.CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998;70(5): 1781-92
  • 5Brooks BR,Cedarbaum JM.A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary n eurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996;46(5): 1244-9
  • 6Tria MA,Fusco M,Vantini G,et al. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 1994; 127(2): 178-83
  • 7Horikawa I,Miwa T,Ishimaru T,et al. TrkA expression in olfactory epithelium and bulb during development.Neuroreport 1999;10(10):2205-8
  • 8Granholm AC,Albeck D,Backman C,et al. A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review.Rev Neurosci 1998;9(1):31-55
  • 9苏振刚,曹晓建,陈骐,傅震.神经生长因子透过血脑屏障的研究进展[J].国外医学(脑血管疾病分册),2003,11(4):290-293. 被引量:8
  • 10Glicksman MA,Hudkins RL,Rotella DP,et al.K-252 derivatives which enhance neurotrophin-induced activity. Offitcial Gazette of the United States Patent and Trademark Office Patents 1996; 1186(2):1210

二级参考文献16

  • 1Shin SU, Friden P, Moran M, et al. Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci, 1995, 92:2820 - 2824.
  • 2Shin SU, Wu D, Ramanathan R. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol, 1997, 158:4797 - 4804.
  • 3Broadwell RD, Baker Cairns BJ, Friden PM, et al. Transcytosis of protein through the mamalian cerebral epithelium and endothelium.III. Receptor-mediated transcytosis through the blood-braia barrier of blood-borne transferrin and antibody against the transferrin receport. Exp Neurol, 1996, 142:47-65.
  • 4Skarhtos S, Yoshikawa T, Pardridge WM. Transport of [ ^125I ]-transferrin through the rat blood-braia barrier. Brain Res, 1995, 683:164 -171.
  • 5Huwyler J, Pardridge WM. Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat braia capillaries. J Neurochem, 1998, 70:883 -886.
  • 6Huwyler J, Wu D, Pardridge WM. Braia drug delivery of small molecules using immnunoliposomes. Proc Natl Acad Sci USA, 1996, 93:14164 - 14169.
  • 7Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rcv, 1999, 36:277 - 290.
  • 8Huwyler J, Yang J, Pardridge WM. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distrbution in the rat. J Pharmacol Exp Ther, 1997, 282:1541 -1546.
  • 9Pardridge WM. Vector-mediated drug delivery to the brain. Adv Drug Deliv Rev. 1999, 36:299 -321.
  • 10Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem, 1998, 70:1781 - 1792.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部